@article{ref1,
title="Serum S100-B as a tool to predict computed cranial tomography findings in mild brain injury",
journal="Injury prevention",
year="2010",
author="Zongo, D. and Ribereau-Gayon, R. and Masson, F. and Lagarde, E.",
volume="16",
number="Suppl 1",
pages="A63-A64",
abstract="Safety 2010 World Injury Conference, London, Abstract: :  Background Minor head injury (MHI) has a high incidence and implies a risk of brain injury. Cranial computed tomography (CCT) is recommended for early detection of these lesions. However the indication of CCT is based on non specific clinical symptoms. Protein S100-B was then suggested as a promising tool to identify those patients with no risk of cranial injury.Objective To evaluate S100-B as a screening tool in the management of MHI.Methods Patients attending Bordeaux emergency department with an isolated MHI were consecutively included during 15 months. Blood samples were drawn within 6 h after head injury to assess S100-B level.Results 1559 patients were included. CCT was indicative of cranial injury in 112 patients (7%). At the threshold of 0.10 g/l, S100B has a sensitivity of 99% (95% CI 95 to 100), a specificity of 12% (11-14) and a negative predictive value (NPV) of 99% (97-100) as compared with CCT results. 12% of the patients has a S110-B level below this threshold and therefore could have been discharged with CCT. A threshold of 0.12μg/L proved however to be the best compromise between sensitivity (99%), specificity (20%) and a NPV of 99.7% (98-100) with CCT potentially avoided for 19% of the patients.Discussion Early determination of S100-B blood levels is highly sensitive to detect CCT abnormalities. The threshold of 0.12 μg/L was the best compromise between sensitivity and specificity in our study.<p />",
language="en",
issn="1353-8047",
doi="10.1136/ip.2010.029215.231",
url="http://dx.doi.org/10.1136/ip.2010.029215.231"
}